請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78354
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王錦堂(Jin-Town Wang) | |
dc.contributor.author | Chia-Ling Wu | en |
dc.contributor.author | 吳珈菱 | zh_TW |
dc.date.accessioned | 2021-07-11T14:52:42Z | - |
dc.date.available | 2025-08-03 | |
dc.date.copyright | 2020-09-10 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-03 | |
dc.identifier.citation | 1. Torres, J., et al., Crohn's disease. Lancet, 2017. 389(10080): p. 1741-55. 2. Wei, S.-C., et al., Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intestinal research, 2017. 15(3): p. 285-310. 3. Molodecky, N.A., et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology, 2012. 142(1): p. 46-54. 4. Ng, S.C., et al., Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology, 2013. 145(1): p. 158-65.e2. 5. Kuo, C.J., et al., The Trend of Inflammatory Bowel Diseases in Taiwan: A Population-Based Study. Dig Dis Sci, 2015. 60(8): p. 2454-62. 6. Wei, S.C., et al., A nationwide population-based study of the inflammatory bowel diseases between 1998 and 2008 in Taiwan. BMC Gastroenterol, 2013. 13: p. 166. 7. Susan, L.G., A.H. Steinhart, and R.G. Gordon, Combination Ciprofloxacin and Metronidazole for Active Crohn’s Disease. Can J Gastroenterol, 1998. 12(1): p. 53-6. 8. Liu, Y., et al., Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology, 1995. 108(5): p. 1396-404. 9. Darfeuille-Michaud, A., et al., Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology, 1998. 115(6): p. 1405-13. 10. Giaffer, M.H., C.D. Holdsworth, and B.I. Duerden, Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut, 1992. 33(5): p. 646-50. 11. Martinez-Medina, M. and L.J. Garcia-Gil, Escherichia coli in chronic inflammatory bowel diseases: An update on adherent invasive Escherichia coli pathogenicity. World J Gastrointest Pathophysiol, 2014. 5(3): p. 213-27. 12. Palmela, C., et al., Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut, 2018. 67(3): p. 574-87. 13. Hansen, J.J. and R.B. Sartor, Therapeutic Manipulation of the Microbiome in IBD: Current Results and Future Approaches. Curr Treat Options Gastroenterol, 2015. 13(1): p. 105-20. 14. Chassaing, B., et al., AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition. Gut, 2014. 63(7): p. 1069-80. 15. Barnich, N., et al., CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest, 2007. 117(6): p. 1566-74. 16. Miquel, S., et al., Complete genome sequence of Crohn's disease-associated adherent-invasive E. coli strain LF82. PLoS One, 2010. 5(9). 17. Buckles, E.L., et al., Role of the K2 capsule in Escherichia coli urinary tract infection and serum resistance. J Infect Dis, 2009. 199(11): p. 1689-97. 18. Conte, M.P., et al., Adherent-invasive Escherichia coli (AIEC) in pediatric Crohn's disease patients: phenotypic and genetic pathogenic features. BMC research notes, 2014. 7: p. 748. 19. Sinderen, S.M.G.a.D.v., Bacteriophage: Genetics and Molecular Biology. July 2007. 20. Viertel, T.M., K. Ritter, and H.-P. Horz, Viruses versus bacteria—novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother, 2014. 69(9): p. 2326-36. 21. Winget, D.M., et al., Tangential flow diafiltration: an improved technique for estimation of virioplankton production. Aquat Microb Ecol, 2005. 41: p. 221-32. 22. Labrie, S.J., J.E. Samson, and S. Moineau, Bacteriophage resistance mechanisms. Nat Rev Microbiol, 2010. 8(5): p. 317-27. 23. Keen, E.C., Phage therapy: concept to cure. Front Microbiol, 2012. 3: p. 238. 24. Hsieh, P.F., et al., D-galactan II is an immunodominant antigen in O1 lipopolysaccharide and affects virulence in Klebsiella pneumoniae: implication in vaccine design. Front Microbiol, 2014. 5: p. 608. 25. Galtier, M., et al., Bacteriophages Targeting Adherent Invasive Escherichia coli Strains as a Promising New Treatment for Crohn's Disease. J Crohns Colitis, 2017. 11(7): p. 840-7. 26. Agus, A., et al., Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies. Biomed Res Int, 2014. 2014: p. 567929. 27. Bagley, S.T., Habitat association of Klebsiella species. Infect Control, 1985. 6(2): p. 52-8. 28. Lin, Y.T., et al., Seroepidemiology of Klebsiella pneumoniae colonizing the intestinal tract of healthy Chinese and overseas Chinese adults in Asian countries. BMC Microbiol, 2012. 12: p. 13. 29. Podschun, R. and U. Ullmann, Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev, 1998. 11(4): p. 589-603. 30. Pan, Y.J., et al., Capsular polysaccharide synthesis regions in Klebsiella pneumoniae serotype K57 and a new capsular serotype. J Clin Microbiol, 2008. 46(7): p. 2231-40. 31. Hsu, C.R., et al., Isolation of a bacteriophage specific for a new capsular type of Klebsiella pneumoniae and characterization of its polysaccharide depolymerase. PLoS One, 2013. 8(8): p. e70092. 32. Pope, J.V., et al., Klebsiella pneumoniae liver abscess: an emerging problem in North America. J Emerg Med, 2011. 41(5): p. e103-5. 33. Pastagia, M. and V. Arumugam, Klebsiella pneumoniae liver abscesses in a public hospital in Queens, New York. Travel Med Infect Dis, 2008. 6(4): p. 228-33. 34. Wang, J.H., et al., Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis, 1998. 26(6): p. 1434-8. 35. Siu, L.K., et al., Klebsiella pneumoniae liver abscess: a new invasive syndrome. Lancet Infect Dis, 2012. 12(11): p. 881-7. 36. Fang, C.T., et al., Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis, 2007. 45(3): p. 284-93. 37. Bush, K. and G.A. Jacoby, Updated functional classification of beta-lactamases. Antimicrob Agents Chemother, 2010. 54(3): p. 969-76. 38. Bradford, P.A., Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical microbiology reviews, 2001. 14(4): p. 933-51. 39. Chaves, J., et al., SHV-1 beta-lactamase is mainly a chromosomally encoded species-specific enzyme in Klebsiella pneumoniae. Antimicrob Agents Chemother, 2001. 45(10): p. 2856-61. 40. Lin, W.P., et al., The Antimicrobial Susceptibility of Klebsiella pneumoniae from Community Settings in Taiwan, a Trend Analysis. Sci Rep, 2016. 6: p. 36280. 41. Bratu, S., et al., Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med, 2005. 165(12): p. 1430-5. 42. Papp-Wallace, K.M., et al., Carbapenems: past, present, and future. Antimicrob Agents Chemother, 2011. 55(11): p. 4943-60. 43. Lombardi, F., et al., Emergence of Carbapenem-Resistant Klebsiella pneumoniae: Progressive Spread and Four-Year Period of Observation in a Cardiac Surgery Division. BioMed research international, 2015. 2015: p. 871947. 44. Goren, M.G., et al., Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient. Emerg Infect Dis, 2010. 16(6): p. 1014-7. 45. CDC, T., Annual Report of Nosocomial Infections Surveillance System. 2016. 46. Jones, R.N. and M.A. Pfaller, Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin Microbiol Infect, 2003. 9(7): p. 708-12. 47. Olaitan, A.O., S. Morand, and J.M. Rolain, Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol, 2014. 5: p. 643. 48. Yahav, D., et al., Colistin: new lessons on an old antibiotic. Clin Microbiol Infect, 2012. 18(1): p. 18-29. 49. Hendlin, D., et al., Phosphonomycin, a new antibiotic produced by strains of streptomyces. Science, 1969. 166(3901): p. 122-3. 50. Rose, W.E. and M.J. Rybak, Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy, 2006. 26(8): p. 1099-110. 51. Barreteau, H., et al., Cytoplasmic steps of peptidoglycan biosynthesis. FEMS Microbiol Rev, 2008. 32(2): p. 168-207. 52. Typas, A., et al., From the regulation of peptidoglycan synthesis to bacterial growth and morphology. Nat Rev Microbiol, 2011. 10(2): p. 123-36. 53. Nikolaidis, I., S. Favini-Stabile, and A. Dessen, Resistance to antibiotics targeted to the bacterial cell wall. Protein Sci, 2014. 23(3): p. 243-59. 54. Dengler, V., et al., Induction kinetics of the Staphylococcus aureus cell wall stress stimulon in response to different cell wall active antibiotics. BMC Microbiol, 2011. 11: p. 16. 55. Silver, L.L., Fosfomycin: Mechanism and Resistance. Cold Spring Harb Perspect Med, 2017. 7(2). 56. Kim, D.H., et al., Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. Biochemistry, 1996. 35(15): p. 4923-8. 57. Wagenlehner, F.M.E., et al., Uncomplicated urinary tract infections. Deutsches Arzteblatt international, 2011. 108(24): p. 415-23. 58. Schito, G.C., Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents, 2003. 22 Suppl 2: p. 79-83. 59. Falagas, M.E., et al., Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents, 2009. 34(2): p. 111-20. 60. Neuner, E.A., et al., Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother, 2012. 56(11): p. 5744-8. 61. Falagas, M.E., et al., Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis, 2010. 10(1): p. 43-50. 62. Michalopoulos, A., et al., Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect, 2010. 16(2): p. 184-6. 63. Castaneda-Garcia, A., J. Blazquez, and A. Rodriguez-Rojas, Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance. Antibiotics (Basel), 2013. 2(2): p. 217-36. 64. Island, M.D. and R.J. Kadner, Interplay between the membrane-associated UhpB and UhpC regulatory proteins. J Bacteriol, 1993. 175(16): p. 5028-34. 65. Dahl, J.L., B.Y. Wei, and R.J. Kadner, Protein phosphorylation affects binding of the Escherichia coli transcription activator UhpA to the uhpT promoter. J Biol Chem, 1997. 272(3): p. 1910-9. 66. Takahata, S., et al., Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents, 2010. 35(4): p. 333-7. 67. Horii, T., et al., Emergence of fosfomycin-resistant isolates of Shiga-like toxin-producing Escherichia coli O26. Antimicrob Agents Chemother, 1999. 43(4): p. 789-93. 68. Tseng, S.P., et al., The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan. J Microbiol Immunol Infect, 2017. 50(5): p. 653-61. 69. Salama, N.R., B. Shepherd, and S. Falkow, Global transposon mutagenesis and essential gene analysis of Helicobacter pylori. J Bacteriol, 2004. 186(23): p. 7926-35. 70. Kuo, L.C., et al., Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance study. Int J Antimicrob Agents, 2008. 31(5): p. 420-6. 71. Miller, V.L. and J.J. Mekalanos, A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR. J Bacteriol, 1988. 170(6): p. 2575-83. 72. Fang, C.T., et al., A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med, 2004. 199(5): p. 697-705. 73. Muronets, E.M., A.N. Dubeikovskii, and S.V. Kameneva, [Mobilization of the pACYC184 plasmid by hybrid pAS8-121 delta plasmids in Escherichia coli cells]. Mol Gen Mikrobiol Virusol, 1987(2): p. 12-6. 74. Hsieh, P.-F., et al., Serum-Induced Iron-Acquisition Systems and TonB Contribute to Virulence in Klebsiella pneumoniae Causing Primary Pyogenic Liver Abscess. J Bacteriol, 2008. 197(12): p. 1717-27. 75. Herrero, M., V. de Lorenzo, and K.N. Timmis, Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram-negative bacteria. J Bacteriology, 1990. 172(11): p. 6557-67. 76. Green, M.R., J. Sambrook, and J. Sambrook, Molecular cloning : a laboratory manual. Vol. 4th. 2012: Cold Spring Harbor Press. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78354 | - |
dc.description.abstract | 克隆氏症(Crohn's disease, CD)為發炎性大腸疾病(Inflammatory bowel disease, IBD)的一種,屬於慢性的腸道發炎疾病且容易復發。目前有研究指出,黏附侵襲性大腸桿菌(Adherent-invasive E. coli, AIEC)與克隆氏症有關,克隆氏症的治療方法主要針對疾病中的過度免疫反應,以抗發炎藥物為主,但近年來也有針對腸內菌的標靶療法被提出,噬菌體療法屬於其中之一。在本篇研究中,希望藉由建構AIEC的突變菌株庫,找出噬菌體所辨認的標的受體。先前本實驗室研究中,已經從污水中分離出可以感染LF82(AIEC之人類參考菌株)的噬菌體ФLF82,以及可感染LI60C3(小鼠腸胃道分離出的AIEC)的噬菌體ФLI60C3。我們一開始推測莢膜有可能作為噬菌體的受體而感染宿主,透過pKO3質體帶有四環黴素(Tetracycline)抗藥基因,去置換AIEC LF82莢膜形成的相關基因,成功建構了帶有抗藥性基因的AIEC LF82莢膜缺失菌株,但發現噬菌體對其感染效率並無減低。而後利用pUT-Km1質體帶有mini-Tn5跳躍基因建構AIEC LI60C3的跳躍子突變基因庫(Transposon mutant library),並收集了2688株突變菌株,實驗結果發現噬菌體對其感染能力並無下降,因此推測此突變基因庫中跳躍子插入的位置,並沒有剔除到影響AIEC噬菌體感染力的基因。 細菌抗藥性在全世界日趨嚴重,早期開發的磷黴素(Fosfomycin)也重新被檢視,磷黴素毒性低、殺菌力強,且對產生廣效性乙內醯胺酶(Extended spectrum beta-lactamase;ESBL)分解酶的腸內菌具有高度感受性,但也有抗藥性菌株的發現。本實驗室先前測試15株CRKP後發現,這些菌株對磷黴素具有抗性,且最小抑制濃度(Minimum inhibitory concentration;MIC)為256 µg/mL或512 µg/mL,稱為低抗性菌株。在本篇研究中,以定量逆轉錄聚合酶連鎖反應測定這些低抗性菌株之fosA基因,與對磷黴素具感受性之NTUH-K2044菌株相比並沒有過度表現,而後將其fosA基因序列進行定序,並同樣利用NTUH-K2044菌株進行比對,結果顯示低抗性菌株之FosA蛋白質的第91個胺基酸皆為纈胺酸(Valine),而NTUH-K2044則為異白胺酸(Isoleucine),我們推測此胺基酸的變異可能與低抗性菌株之抗藥機制相關,透過pKO3質體成功建構NTUH-K2044胺基酸置換突變株(Ile91Val)後,利用最小抑菌濃度試驗測得磷黴素對其最小抑制濃度由64 µg/ml上升至256 µg/ml,提升了4倍,證實這些低抗性菌株的抗藥機制與FosA蛋白質上第91個胺基酸的改變有關。 | zh_TW |
dc.description.abstract | Crohn's disease is a kind of inflammatory bowel disease, which belongs to chronic intestinal inflammatory disease and is prone to recurrence. Many studies indicate that adherent-invasive Escherichia coli(AIEC)are pathogenic bacteria associated with human Crohn's disease. Targeted therapies directed against intestinal bacteria were proposed, and phage therapy is one of them. In this study, we aim to use phage therapy to eliminate AIEC from the inflamed intestinal mucosa in mice and to identify the target receptor recognized by the phage through establishing AIEC transposon mutant library. In the previous laboratory study, ФLF82 and ФLI60C3, which can infect LF82(AIEC human reference strain)and LI60C3(AIEC isolated from mouse gastrointestinal tract), respectively, have been isolated from sewage. According to previous studies, whether the capsule was the receptor for AIEC phage to infect the host became our testing objective. The pKO3 plasmid carrying the Tetracycline resistance gene was utilized to replace the AIEC LF82 capsular-forming gene. However, the AIEC LF82 capsular-deficient strain was found to have no reduction in phage infectivity. We used the pUT-Km1 plasmid with the mini-Tn5 transposon gene to construct the AIEC LI60C3 transposon mutant library and collected 2688 mutant strains. The results showed that the infectivity of ФLI60C3 in these mutants is not declining. Thus, the insertion positions of the transposon in this mutant gene pool didn’t target the gene which might affect the infectivity of ФLI60C3. With the issue of carbapenem-resistant Klebsiella pneumoniae(CRKP)as a rising concern, fosfomycin is one of the last-line antibiotic candidates due to its low toxicity and efficiency of clearing bacteria. Unfortunately, the fosfomycin resistant strains have been found. According to the previous study, we confirmed 15 CRKPs strains through the minimum inhibitory concentration(MIC)test of fosfomycin, and observed that these strains were low-resistant to fosfomycin(MIC = 256-512 µg/ml). In this study, since the resistant mechanisms were unknown, we sequenced chromosomal fosA gene in these strains and used quantitative reverse transcription-polymerase chain reaction(qRT-PCR)to determine the expression level of fosA gene. The results showed that, compared with NTUH-K2044 strain which was susceptible to fosfomycin, fosA gene of low-resistant strains was not overexpressed. On the other hand, the results indicated that an amino acid substitution in the FosA protein(I91V)was detected. Based on this examination, we speculated that this missense mutation in FosA contributed to low level fosfomycin resistance. Subsequently, site-directed mutagenesis was used to generate fosA loci harboring individual missense mutation; introduction of the mutated genes into NTUH-K2044 strain, resulted in 64- to 256-fold increases in fosfomycin MICs. In conclusion, we hypothesized that novel individual FosA amino acid substitution(I91V)was responsible for low level fosfomycin resistance. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:52:42Z (GMT). No. of bitstreams: 1 U0001-2707202015553400.pdf: 2666611 bytes, checksum: 5b4e775de8915c8902fc3aab35cbf55a (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 口試委員審定書 i 致謝 ii 中文摘要 iii ABSTRACT v 目錄 vii 表目錄 x 圖目錄 xi 第一章、緒論 1 1.1 克隆氏症 1 1.2 克隆氏症的成因及治療 1 1.3 黏附侵襲性大腸桿菌 2 1.4 噬菌體…………………………………………………………………………….3 1.4.1 噬菌體簡介 3 1.4.2 細菌與噬菌體間的辨識 4 1.4.3 噬菌體治療 5 1.5 克雷伯氏肺炎桿菌 5 1.6 超廣效β-內醯氨酶之克雷伯氏肺炎桿菌 6 1.7 抗碳青黴烯類抗生素的克雷伯氏肺炎桿菌 7 1.8 克雷伯氏肺炎桿菌的用藥演進與多重抗藥性治療 8 1.9 磷黴素 8 1.10 磷黴素之抗藥性機轉 9 1.12 研究動機 11 第二章、實驗材料與方法 12 2.1 實驗材料 12 2.1.1 細菌菌株、噬菌體與質體 12 2.1.2 培養基…………………………………………………………………………12 2.1.3 抗生素濃度 12 2.1.4 引子 12 2.2 實驗方法 12 2.2.1 噬菌體增殖 12 2.2.2 噬菌體沉澱……………………………………………………………………13 2.2.3 點試驗 13 2.2.4 建構AIEC LF82之莢膜缺失突變株 13 2.2.5 建立跳躍子突變株庫 14 2.2.6 半隨機聚合酶連鎖反應 15 2.2.7 抗生素感受性試驗 16 2.2.8 偵測基因表現量 16 2.2.9 建構低抗性菌株之fosA基因剃除突變株 17 2.2.10 建構NTUH-K2044之胺基酸置換突變株 18 第三章、實驗結果 19 3.1 建構LF82之莢膜缺失菌株 19 3.2 建構LF82菌株之跳躍子突變株庫 19 3.3 建構LI60C3菌株之跳躍子突變株庫 19 3.4 篩選LI60C3菌株之跳躍子突變株庫 20 3.5 CRKP對磷黴素之最小抑菌濃度試驗 20 3.6 建構低抗性菌株之fosA基因剃除突變株 21 3.6 偵測不同菌株間fosA基因表現量 21 3.7 比較不同菌株之FosA蛋白質序列 21 3.8 建構NTUH-K2044菌株之胺基酸置換突變株 21 第四章、討論 23 第五章、參考文獻 26 附錄 56 | |
dc.language.iso | zh-TW | |
dc.title | 尋找黏附侵襲性大腸桿菌噬菌體之受體位置與克雷伯氏肺炎桿菌之磷黴素抗藥性機轉 | zh_TW |
dc.title | Searching for adherent-invasive Escherichia coli phage receptor and mechanism(s) mediating low level fosfomycin resistance in Klebsiella pneumoniae | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 董馨蓮(Sin-Lian Dong),莊依萍(Yi-Ping Chuang) | |
dc.subject.keyword | 克隆氏症,黏附侵襲性大腸桿菌,噬菌體,跳躍子突變基因庫,克雷伯氏肺炎桿菌,磷黴素,抗藥性,FosA, | zh_TW |
dc.subject.keyword | Crohn’s disease,Adherent-invasive E. coli,bacteriophage,Klebsiella pneumoniae,fosfomycin,drug resistance,FosA, | en |
dc.relation.page | 57 | |
dc.identifier.doi | 10.6342/NTU202001917 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-08-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
dc.date.embargo-lift | 2025-08-03 | - |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-2707202015553400.pdf 目前未授權公開取用 | 2.6 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。